Step 1 of 2
These downloadable slides focus on the recognition and management of adverse events associated with CAR T-cell therapies and bispecific antibodies in patients with hematologic malignancies, with a focus on emergency department care. The slides review the clinical manifestations, timing, and grading of CRS and ICANS, including differentiation from infection, stroke, and other acute conditions. Evidence-based approaches to initial assessment, stabilization, treatment, and escalation of care are highlighted, along with product-specific monitoring requirements and delayed toxicities. Practical strategies for identifying treatment exposure, navigating evolving REMS requirements, and coordinating care across emergency medicine, oncology, and pharmacy teams are also addressed to support timely intervention and appropriate clinical decision-making.